Exicure Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Exicure has been growing earnings at an average annual rate of 10.1%, while the Biotechs industry saw earnings growing at 15.5% annually. Revenues have been growing at an average rate of 22.7% per year.
Wichtige Informationen
10.1%
Wachstumsrate der Gewinne
26.4%
EPS-Wachstumsrate
| Biotechs Wachstum der Industrie | 17.0% |
| Wachstumsrate der Einnahmen | 22.7% |
| Eigenkapitalrendite | -604.3% |
| Netto-Marge | -2,667.2% |
| Letzte Ertragsaktualisierung | 31 Mar 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding
Aug 29
Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities
Sep 26Exicure Q2 GAAP loss per share narrows, revenue up
Aug 15Exicure regains compliance with Nasdaq's minimum bid price requirement
Jul 20Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance
Jun 29Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?
Aug 25Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?
Mar 10A Look At Exicure's (NASDAQ:XCUR) Share Price Returns
Jan 13Exicure announces issuance of two new U.S. patents, and new patent allowance
Dec 21How Much Of Exicure, Inc. (NASDAQ:XCUR) Do Institutions Own?
Dec 15Aufschlüsselung der Einnahmen und Ausgaben
Wie Exicure Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Mar 24 | 1 | -13 | 11 | 0 |
| 31 Dec 23 | 0 | -17 | 13 | 0 |
| 30 Sep 23 | 22 | 3 | 12 | 1 |
| 30 Jun 23 | 24 | 3 | 12 | -13 |
| 31 Mar 23 | 26 | 1 | 11 | 0 |
| 31 Dec 22 | 29 | -3 | 11 | 0 |
| 30 Sep 22 | 9 | -35 | 13 | 0 |
| 30 Jun 22 | 3 | -53 | 13 | 14 |
| 31 Mar 22 | 1 | -60 | 13 | 0 |
| 31 Dec 21 | 0 | -64 | 13 | 0 |
| 30 Sep 21 | -2 | -63 | 12 | 0 |
| 30 Jun 21 | 4 | -48 | 11 | 0 |
| 31 Mar 21 | 8 | -38 | 10 | 0 |
| 31 Dec 20 | 17 | -25 | 10 | 0 |
| 30 Sep 20 | 17 | -22 | 9 | 0 |
| 30 Jun 20 | 15 | -19 | 9 | 0 |
| 31 Mar 20 | 10 | -20 | 9 | 0 |
| 31 Dec 19 | 1 | -26 | 9 | 0 |
| 30 Sep 19 | 1 | -21 | 8 | 0 |
| 30 Jun 19 | 1 | -21 | 8 | 0 |
| 31 Mar 19 | 0 | -22 | 8 | 0 |
| 31 Dec 18 | 0 | -22 | 8 | 0 |
| 30 Sep 18 | 2 | -21 | 8 | 0 |
| 30 Jun 18 | 5 | -18 | 8 | 0 |
| 31 Mar 18 | 7 | -14 | 8 | 0 |
| 31 Dec 17 | 10 | -11 | 7 | 0 |
| 30 Sep 17 | 8 | -13 | 6 | 0 |
| 30 Jun 17 | 6 | -15 | 5 | 0 |
| 31 Mar 17 | 3 | -16 | 4 | 0 |
| 31 Dec 16 | 1 | -17 | 4 | 0 |
| 31 Dec 15 | 2 | -6 | 5 | 0 |
Qualität der Erträge: XCUR is currently unprofitable.
Wachsende Gewinnspanne: XCUR ist derzeit unrentabel.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: XCUR ist unrentabel, hat aber in den letzten 5 Jahren die Verluste mit einer Rate von 10.1% pro Jahr reduziert.
Beschleunigtes Wachstum: Unable to compare XCUR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: XCUR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: XCUR has a negative Return on Equity (-604.26%), as it is currently unprofitable.